Drugs

Exam Prep

Glossary

Handouts

SchoolsNew

Contact Lenses Medications Glossary Calculators Handouts Exam Prep

Disclaimer Privacy Policy Terms of Use Contact

Educational resource only — not medical advice. Independent study tool, not affiliated with or endorsed by the NBEO®. See our Disclaimer.

Medications›Allergy›Zaditor

Zaditor®

GoodRx

ketotifen 0.025%, 0.035% · ophthalmic solution

Allergy

Same formulation, different label. Identical to Alaway®. Choose on price and availability, not on the drug.

Approved uses

Allergic conjunctivitis, ocular itching

1 drop in the affected eye(s) BID, every 8 to 12 hours

Itch relief begins within 15 minutes of instillation and lasts at least 8 hours.

Contraindications

Sensitivity to any ingredient in the product.
Contact lens related irritation.

Available Forms

Ophthalmic solution, ketotifen fumarate 0.25 mg/mL, 5 mL and 10 mL dropper bottles, 10 mL also packaged two per carton

Mechanism of Action

H1 receptor antagonist that also stabilizes mast cells and inhibits eosinophil chemotaxis and activation, blocking the itch mediator while limiting further mediator release. That dual action gives onset within 15 minutes and effect persisting at least 8 hours after a single drop.

Warnings & Precautions

Contact lenses: Remove before instillation and wait at least 10 minutes before reinserting; not for contact lens related irritation.

Other brands of this exact formulation

Alaway®

Other Allergy drugs

Alocril®
Alomide®
Alrex®
Bepreve®
Crolom®
Elestat®
Inflamase Forte®
Lastacaft®

Browse all medications All Allergy drugs

Solution appearance: Discard if it changes color or becomes cloudy.

Persistent symptoms: Eye pain, changes in vision, redness, or itching that worsens or lasts more than 72 hours warrants reevaluation.

Tip contamination: Do not touch the container tip to any surface, and replace the cap after each use.

Common Side Effects

Ocular: Instillation discomfort. In a masked contralateral-eye comparison, treated eyes were rated significantly less comfortable than olopatadine 0.1% immediately after instillation (mean 2.09 vs 1.25).
Systemic: None drug-related in a randomized pediatric trial dosing BID for 4 weeks; ocular adverse event rates matched placebo and no subject discontinued for an adverse event.

Pregnancy & Lactation

Animal studies of toxic doses did not reveal evidence of teratogenecity. No human data is available.

Pediatric Use

Labeled for ages 3 and older; efficacy with placebo-level ocular tolerability shown in a randomized trial in 8 to 16 year olds.

Zaditor (ketotifen 0.025%, 0.035%) | EyeKnow O.D.